This morning we watched CVS Health drop -2.6% to a price of $63.3 per share. The Large-Cap Pharmaceutical Retail company is now trading -7.05% below its average target price of $68.1. Analysts have set target prices ranging from $60.0 to $91.12 per share for CVS Health, and have given the stock an average rating of buy.
The stock has a very low short interest at 1.6%, and a short ratio of 2.27. The company's insiders own 0.12% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 83.1% of CVS Health's shares being owned by this investor type.
Institutions Invested in CVS Health
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Vanguard Group Inc | 9% | 116,350,122 | $7,364,730,061 |
| 2024-06-30 | Blackrock Inc. | 8% | 100,151,218 | $6,339,371,830 |
| 2024-06-30 | Dodge & Cox Inc | 5% | 61,683,343 | $3,904,432,265 |
| 2024-06-30 | Capital World Investors | 4% | 56,023,849 | $3,546,197,612 |
| 2024-06-30 | State Street Corporation | 4% | 54,538,843 | $3,452,199,702 |
| 2024-06-30 | Capital Research Global Investors | 3% | 35,455,509 | $2,244,262,820 |
| 2024-06-30 | FMR, LLC | 2% | 29,371,944 | $1,859,185,321 |
| 2024-06-30 | Geode Capital Management, LLC | 2% | 25,900,104 | $1,639,424,791 |
| 2024-06-30 | Morgan Stanley | 2% | 22,860,551 | $1,447,027,164 |
| 2024-06-30 | Capital International Investors | 2% | 20,737,675 | $1,312,653,359 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on CVS Health.
